Vanessa Broadhurst

Executive Vice President, Global Corporate Affairs Johnson & Johnson

Last Reviewed: October 3, 2026

Executive Summary

Vanessa Broadhurst has been Executive Vice President, Global Corporate Affairs at Johnson & Johnson since 2022, a member of its executive committee responsible for corporate marketing, global communications, global health equity, and worldwide government affairs and policy. Her background is commercial rather than communications: she spent more than 25 years running pharmaceutical businesses at Amgen, Novartis, Abbott and J&J in the United States and Europe, and before her current role led commercial and launch strategy across J&J’s pharmaceutical therapeutic areas. She is a director of the animal health company Zoetis. She came to corporate affairs from the commercial side of pharmaceuticals rather than from communications or policy.

Career Highlights

• Executive Vice President, Global Corporate Affairs at Johnson & Johnson since 2022.
• Company Group Chairman, Global Commercial Strategy Organization, from 2018.
• General manager at Amgen in inflammation, cardiovascular and bone, 2013 to 2017.
• Director of Zoetis.

Professional Journey

Broadhurst earned a bachelor’s degree at the University of Colorado Boulder and an MBA at the University of Michigan’s Ross School of Business. Her career has included roles at Novartis and Abbott in the United States and Europe, according to her J&J biography.

She first worked at Johnson & Johnson from 2005 to 2013 in leadership roles, leading U.S. business units including cardiovascular and metabolism, internal medicine and infectious disease. From 2013 to 2017 she was a general manager at Amgen, in inflammation and cardiovascular and then cardiovascular and bone.

She rejoined J&J in 2017 and in 2018 became company group chairman of the Global Commercial Strategy Organization for the pharmaceuticals business, leading commercialization and launch strategy across six therapeutic areas and overseeing global value and access, commercial data sciences and medical affairs, with seats on the pharmaceuticals group operating committee and the R&D senior leadership team.

In 2022 she was named executive vice president, global corporate affairs and joined the executive committee. She now oversees corporate marketing, global communications, global health equity, and worldwide government affairs and policy. J&J operates two businesses, Innovative Medicine and MedTech, and its Innovative Medicine business alone exceeds $60 billion in annual revenue, according to the company. Outside J&J she is a director of Zoetis and a member of The Executive Leadership Council.

Like chief information officer James Swanson, she left J&J and later returned to join its executive committee. Her current remit combines the company’s external voice, through communications and marketing, with its dealings with governments on health policy and its global health equity work.

Education

University of Michigan, Ross School of Business

MBA

University of Colorado Boulder

Bachelor of Arts